Hannah Dry

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu et al. · The Lancet Oncology · 2023 · 182 citations

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +10

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Eeva Sommer, Hannah Dry, Darren A.E. Cross et al. · Biochemical Journal · 2013 · 160 citations · Full text

Breast Oncology, Akt Protein Kinase, Cancer Biology +16

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong et al. · Journal of Clinical Oncology · 2021 · 105 citations

Poor Clinical Outcomes, Breast Oncology, Immunology +23

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson et al. · Molecular Cancer Therapeutics · 2014 · 99 citations · Full text

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

Jonathan E. Rosenberg, Se Hoon Park, Vadim Kozlov et al. · Journal of Clinical Oncology · 2022 · 47 citations · Full text